Pantelis Karatzas
National and Kapodistrian University of Athens
Quality of lifeInternal medicineSurgeryRetrospective cohort studyAdverse effectImmunologyAzathioprineInfliximabInflammatory bowel diseaseEndoscopyDiscontinuationDiseaseCrohn's diseaseSingle CenterAdalimumabUlcerative colitisIn patientMedicineGastroenterology
41Publications
11H-index
354Citations
Publications 41
Newest
#1Giorgos Bamias (UoA: National and Kapodistrian University of Athens)H-Index: 34
#2G KokkotisH-Index: 2
view all 41 authors...
Objectives null COVID-19 has evolved into a global health crisis, variably affecting the management of patients with chronic illnesses. Patients with inflammatory bowel disease (IBD) may represent a vulnerable population due to frequent administration of immune-modifying treatments. We aimed to depict the natural history of COVID-19 infection in Greek patients with IBD at a nationwide level via unbiased reporting of all cases that were registered during the sequential waves of the pandemic. null...
Source
Anemia is a common extraintestinal manifestation of Inflammatory Bowel Disease (IBD) affecting negatively the patients’ quality of life. The aim of this study was to determine the frequency and real-life management of anemia in IBD patients in Greece. This study was conducted in 17 Greek IBD referral centers. Demographic, clinical, laboratory, IBD and anemia treatment data were collected and analyzed retrospectively. A total of 1394 IBD patients [560 ulcerative colitis (UC), 834 Crohn’s disease ...
Source
#3Theodoros Voulgaris (UoA: National and Kapodistrian University of Athens)H-Index: 4
#4E Laoudi (UoA: National and Kapodistrian University of Athens)
Source
Source
BACKGROUND AND AIMS This real-world study assessed the impact of golimumab on health-related quality of life (HRQoL) and other patient-reported outcomes (PROs) in patients with ulcerative colitis over 12 months in Greece. METHODS GO-LIFE was a noninterventional, prospective, multicenter, 12-month study. Patients who had moderately-to-severely active ulcerative colitis were naive to antitumor necrosis factor (anti-TNFα) therapy and had failed previous conventional therapy. Patients received golim...
Source
Source
#1Brian Bressler (St. Paul's Hospital)H-Index: 29
#2Andres Yarur (MCW: Medical College of Wisconsin)H-Index: 19
Last. Gerassimos J. MantzarisH-Index: 48
view all 19 authors...
BACKGROUND AND AIMS This study aimed to compare real-world clinical effectiveness and safety of vedolizumab, an α4β7-integrin inhibitor, and anti-tumour necrosis factor-α (anti-TNFα) agents in biologic-naive ulcerative colitis (UC) and Crohn's disease (CD) patients. METHODS This was a 24-month retrospective medical chart study in adult UC and CD patients treated with vedolizumab or anti-TNFα in Canada, Greece and the United States. Inverse probability weighting was used to account for difference...
5 CitationsSource
#1T Voulgaris (UoA: National and Kapodistrian University of Athens)H-Index: 3
#3E Laoudi (UoA: National and Kapodistrian University of Athens)H-Index: 2
Last. Jiannis Vlachogiannakos (UoA: National and Kapodistrian University of Athens)H-Index: 21
view all 11 authors...
Source
#1Nikolaos Kyriakos (UoA: National and Kapodistrian University of Athens)H-Index: 5
Last. Christos LiatsosH-Index: 16
view all 9 authors...
BACKGROUND The prevalence and incidence of inflammatory bowel diseases (IBDs) vary among countries. Data regarding prevalence of IBD in Greece are limited or outdated. METHODS We reviewed the medical records of IBD patients from a population of 551,808 Greek Army recruits in a 13-year period (2006-2018). Study population consisted of males 18-37 of age from Northwest, Central Greece (including Attica), Peloponnese, and Aegean Sea Islands. Age, disease distribution, pharmaceutical treatment and I...
Source
Source